Ask AI
ProCE Banner Activity

TROPiCS-02 Subgroup Analysis by Age: Sacituzumab Govitecan vs Treatment of Physician’s Choice in HR+/HER2- MBC

Conference Coverage
Slideset

In this post hoc analysis of the phase III TROPiCS-02 trial, greater benefit and a manageable safety profile with sacituzumab govitecan vs physician’s choice of treatment was observed across age subgroups in patients with pretreated HR+/HER2- locally advanced/metastatic breast cancer.

Released: December 09, 2023

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Merck Sharp & Dohme, LLC

Seagen Inc.